GIP agonist
GIP receptor agonist
- Glucose-dependent insulin secretion and adipose nutrient handling
- The other incretin (with GLP-1)
- Combined GIP/GLP-1 agonism gives greater weight loss
Drugs with this mechanism (4)
- GIP — The other incretin, and the half of tirzepatide that is not GLP-1.
- Retatrutide — Investigational triple GIP/GLP-1/glucagon agonist for obesity.
- Tirzepatide — Dual GIP/GLP-1 agonist for diabetes and obesity; exceptional glucose and weight effects.
- Tirzepatide (obesity) — Dual GIP/GLP-1 weight-loss drug; also treats obesity-related sleep apnea.
Self-check
- Is GIP-mediated insulin secretion glucose-dependent?
Yes. - Besides insulin secretion, what tissue’s nutrient handling is affected by GIP?
Adipose tissue.
All mechanisms · Open GIP agonist in the interactive console ↗